Cargando…

Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals

SIMPLE SUMMARY: Chronic hepatitis C virus infection is one of the major risk factors for the development of hepatocellular carcinoma. New direct-acting antivirals substantially improved the cure rate of hepatitis C, but the incidence of hepatitis C virus-related hepatocellular carcinoma remains high...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macek Jílková, Zuzana, Seigneurin, Arnaud, Coppard, Celine, Ouaguia, Laurissa, Aspord, Caroline, Marche, Patrice N., Leroy, Vincent, Decaens, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766760/ https://www.ncbi.nlm.nih.gov/pubmed/33352852 http://dx.doi.org/10.3390/cancers12123820

Ejemplares similares

Reply to Comment on “Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
por: Macek Jilkova, Zuzana, et al.
Publicado: (2020)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
por: Dumolard, Lucile, et al.
Publicado: (2023)

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Sex Differences in Spontaneous Degranulation Activity of Intrahepatic Natural Killer Cells during Chronic Hepatitis B: Association with Estradiol Levels
por: Macek Jilkova, Zuzana, et al.
Publicado: (2017)

Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma
por: Mroweh, Mariam, et al.
Publicado: (2020)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment
por: Mroweh, Mariam, et al.
Publicado: (2021)

Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection
por: Ouaguia, Laurissa, et al.
Publicado: (2019)

Hepatitis B virus exploits C‐type lectin receptors to hijack cDC1s, cDC2s and pDCs
por: Ouaguia, Laurissa, et al.
Publicado: (2020)

Control of the Inflammatory Response Mechanisms Mediated by Natural and Induced Regulatory T-Cells in HCV-, HTLV-1-, and EBV-Associated Cancers
por: Ouaguia, Laurissa, et al.
Publicado: (2014)

Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease
por: Macek Jilkova, Zuzana, et al.
Publicado: (2021)

Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma
por: Kurma, Keerthi, et al.
Publicado: (2021)

Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model
por: Kurma, Keerthi, et al.
Publicado: (2022)

Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma
por: Dumolard, Lucile, et al.
Publicado: (2020)

HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation
por: Emamaullee, Juliet A., et al.
Publicado: (2019)

Functions of Liver Natural Killer Cells Are Dependent on the Severity of Liver Inflammation and Fibrosis in Chronic Hepatitis C
por: Fugier, Emilie, et al.
Publicado: (2014)

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
por: Jilkova, Zuzana Macek, et al.
Publicado: (2018)

Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C
por: Malov, S.I., et al.
Publicado: (2021)

Overexpression of Regulatory T Cells Type 1 (Tr1) Specific Markers in a Patient with HCV-Induced Hepatocellular Carcinoma
por: Ouaguia, Laurissa, et al.
Publicado: (2013)

BDCA1(+) cDC2s, BDCA2(+) pDCs and BDCA3(+) cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients
por: Sosa Cuevas, Eleonora, et al.
Publicado: (2020)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
por: Rinaldi, Luca, et al.
Publicado: (2019)

Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells?
por: Macek Jilkova, Zuzana
Publicado: (2022)

CD49b, a Major Marker of Regulatory T-Cells Type 1, Predicts the Response to Antiviral Therapy of Recurrent Hepatitis C after Liver Transplantation
por: Fabien, Stenard, et al.
Publicado: (2014)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Interleukin-6 polymorphisms in HCC patients chronically infected with HCV
por: Adnan, Faisal, et al.
Publicado: (2020)

CD8(+) T Cell Responses during HCV Infection and HCC
por: Hofmann, Maike, et al.
Publicado: (2021)

Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC)
por: Zhao, Pin, et al.
Publicado: (2021)

Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy
por: Villani, Rosanna, et al.
Publicado: (2018)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Hepatitis C Virus (HCV) Evades NKG2D-Dependent NK Cell Responses through NS5A-Mediated Imbalance of Inflammatory Cytokines
por: Sène, Damien, et al.
Publicado: (2010)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020)

Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV
por: Akkiz, H, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lgjnjo2tkud2vf6sltr6sb9bch